NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02329860,Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP),https://clinicaltrials.gov/study/NCT02329860,,COMPLETED,"This was a multicenter, randomized, double-blind, phase III trial. This clinical study evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have progressed on Systemic Therapy (Chemotherapy and/or Targeted Therapy).

Approximately 400 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to Apatinib or placebo (1/3 chance to receive placebo).

Primary endpoint of the study is overall survival.",YES,"Carcinoma, Hepatocellular",DRUG: Apatinib|DRUG: Placebo,"Overall Survival, Approximately 36 months","Time to Progression（TTP）, Approximately 36 months|Progression Free Survival (PFS), Approximately 36 months|Objective Response Rate, Approximately 36 months|Disease Control Rate, Approximately 36 months",,"Jiangsu HengRui Medicine Co., Ltd.",NanJing PLA 81 Hospital,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",APTN-III-HCC,2014-03-26,2017-12-15,2019-08-14,2015-01-01,2024-01-22,2024-01-22,"Jiangsu hengrui medicine CO. LTD, Lianyungang, Jiangsu, 222047, China","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/60/NCT02329860/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/60/NCT02329860/SAP_001.pdf"
